MX2017004420A - Molecula proteica hibrida apta para inhibicion de al menos un antibiotico y composicion farmaceutica que la comprende. - Google Patents

Molecula proteica hibrida apta para inhibicion de al menos un antibiotico y composicion farmaceutica que la comprende.

Info

Publication number
MX2017004420A
MX2017004420A MX2017004420A MX2017004420A MX2017004420A MX 2017004420 A MX2017004420 A MX 2017004420A MX 2017004420 A MX2017004420 A MX 2017004420A MX 2017004420 A MX2017004420 A MX 2017004420A MX 2017004420 A MX2017004420 A MX 2017004420A
Authority
MX
Mexico
Prior art keywords
antibiotic
hybrid
proteinaceous molecule
inhibiting
pharmaceutical composition
Prior art date
Application number
MX2017004420A
Other languages
English (en)
Inventor
Dupret Daniel
SCHUE Mathieu
Jais Philippe
Original Assignee
Azurrx Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Azurrx Sas filed Critical Azurrx Sas
Publication of MX2017004420A publication Critical patent/MX2017004420A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y203/00—Acyltransferases (2.3)
    • C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona con una molécula proteica híbrida que comprende por lo menos dos proteínas aptas para inhibir la actividad de por lo menos un antibiótico, teniendo cada proteína características bioquímicas diferentes, siendo las proteínas unidas entre ellas. La molécula proteica híbrida inhibe la actividad de por lo menos un antibiótico para disminuir los efectos secundarios intestinales de los antibióticos, tales como diarreas agudas inducidas por los antibióticos y las infecciones nosocomiales secundarias a una terapia de antibiótico parenteral.
MX2017004420A 2014-10-16 2015-10-13 Molecula proteica hibrida apta para inhibicion de al menos un antibiotico y composicion farmaceutica que la comprende. MX2017004420A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1459935A FR3027307B1 (fr) 2014-10-16 2014-10-16 Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
PCT/FR2015/052756 WO2016059341A1 (fr) 2014-10-16 2015-10-13 Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant

Publications (1)

Publication Number Publication Date
MX2017004420A true MX2017004420A (es) 2017-10-04

Family

ID=52684326

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004420A MX2017004420A (es) 2014-10-16 2015-10-13 Molecula proteica hibrida apta para inhibicion de al menos un antibiotico y composicion farmaceutica que la comprende.

Country Status (14)

Country Link
US (1) US20170354706A1 (es)
EP (2) EP3207141B1 (es)
JP (1) JP2017533260A (es)
CN (1) CN107108749A (es)
AU (1) AU2015332251A1 (es)
BR (1) BR112017007578A2 (es)
CA (1) CA2964151A1 (es)
DK (1) DK3207141T3 (es)
FR (1) FR3027307B1 (es)
IL (1) IL251582A0 (es)
MX (1) MX2017004420A (es)
RU (1) RU2017115829A (es)
SG (1) SG11201702808WA (es)
WO (1) WO2016059341A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021001394A (es) 2018-08-05 2021-04-12 Da Volterra Metodo para mejorar la eficacia de un agente anticanceroso.
WO2020030593A1 (en) 2018-08-05 2020-02-13 Da Volterra Compositions for the treatment of graft versus host disease
CN110305882A (zh) * 2019-06-21 2019-10-08 广东实验中学 一种降解四环素类抗生素的基因及其编码的酶蛋白
EP4148136A1 (en) 2021-09-08 2023-03-15 Da Volterra An engineered yeast cell for the delivery of antibiotic-inactivating enzymes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2599743B1 (fr) * 1986-06-10 1988-09-30 Pasteur Institut Fragment d'adn comprenant au moins une partie d'un gene de resistance a l'erythromycine, son procede d'obtention et ses applications biochimiques
FI920206A0 (fi) * 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
CN1191363C (zh) * 2002-02-11 2005-03-02 陈秀枢 β－内酰胺酶/氨基糖苷钝化酶融合基因其表达产物其组合物及其应用
FR2843302B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
CN101128187A (zh) * 2005-02-09 2008-02-20 达沃尔泰拉公司 活性剂的结肠递送
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
FI119678B (fi) * 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
FI20105572A0 (fi) * 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
FR2974012A1 (fr) * 2011-04-12 2012-10-19 Univ Nancy 1 Henri Poincare Utilisation de calixarenes dans le traitement des infections bacteriennes

Also Published As

Publication number Publication date
JP2017533260A (ja) 2017-11-09
FR3027307B1 (fr) 2016-11-04
RU2017115829A3 (es) 2019-02-13
WO2016059341A1 (fr) 2016-04-21
US20170354706A1 (en) 2017-12-14
EP3207141B1 (fr) 2019-07-31
FR3027307A1 (fr) 2016-04-22
CA2964151A1 (en) 2016-04-21
EP3207141A1 (fr) 2017-08-23
EP3584321A1 (fr) 2019-12-25
DK3207141T3 (da) 2019-11-04
CN107108749A (zh) 2017-08-29
RU2017115829A (ru) 2018-11-19
IL251582A0 (en) 2017-06-29
SG11201702808WA (en) 2017-05-30
BR112017007578A2 (pt) 2018-02-27
AU2015332251A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
EP3613247A4 (en) COMMON GROUP PDCCH DESIGN IN NO
EP3408326A4 (en) ELASTOMER ARTICLES, COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
EP3359193A4 (en) Novel carbohydrate antibodies, pharmaceutical compositions and uses thereof
SG11201700621XA (en) Antibiotic compositions for treating bacterial infections
BR112015011697A2 (pt) antibióticos macrocíclicos de amplo espectro
NZ724798A (en) Polymyxin derivatives as antimicrobial compounds
EP3316685A4 (en) Lyophilized Pharmaceutical Compositions
MX2018015125A (es) Nuevos compuestos antibacterianos.
WO2014144295A8 (en) Ceftolozane antibiotic compositions
EP3360893A4 (en) HIGH AFFINES AND SOLUBLE PDL-1 MOLECULAR
EP3793737A4 (en) COMBINED CLEANING AND CONCENTRATION BY DETERMINISTIC LATERAL DISPLACEMENT WITH A RECIRCULATION PRODUCT
MX2022006304A (es) Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
BR112018010255A2 (pt) antibióticos macrocíclicos de amplo espectro
MX2017004420A (es) Molecula proteica hibrida apta para inhibicion de al menos un antibiotico y composicion farmaceutica que la comprende.
EP3360050A4 (en) PARALLEL PROCESSING OF SOLUTION SPACE PARTITIONS
BR112018010267A2 (pt) antibióticos macrocíclicos de amplo espectro
MX2017010357A (es) Derivados novedosos de n-acil-arilsulfonamida como inhibidores de aminoacil acido ribonucleico de transferencia (arnt) sintetasa.
HK1254239A1 (zh) 有效對抗多藥耐藥細菌的新的氨基糖苷抗生素
EP3483166A4 (en) IMIDAZOOXAZOLE DERIVATIVE WITH ANTITUMORIC EFFECT AND PHARMACEUTICAL COMPOSITION THEREWITH
PH12018500358A1 (en) Compounds for use in an antibacterial applications
MX363631B (es) Composiciones y metodos para tratar infecciones bacterianas.
EP3356543A4 (en) EXPRESSION SYSTEM FOR MODIFIED BACTERIAL PROTEINS
EP3263604A4 (en) Polysaccharide derivative having membrane-permeable peptide chain
EP3374027A4 (en) RATIONAL DRUG DESIGN FOR TARGETING RESISTANT GRAMNEGATIVE BACTERIAL INFECTIONS AGAINST POLYMYXIN-CLASS ANTIBIOTICS
EP3273797A4 (en) Composition inhibiting gram-positive, pathogenic bacteria